ErbB-3 Monoclonal Antibody

This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the m

Introducing the ERBB-3 Monoclonal Antibody, a highly effective and reliable solution for targeted therapy. This innovative product is designed to specifically target the ERBB-3 receptor, which is known to play a critical role in the development and progression of various types of cancer.

Our ERBB-3 Monoclonal Antibody is produced using state-of-the-art technology and is rigorously tested to ensure its purity, potency, and specificity. It is a monoclonal antibody that binds to the extracellular domain of the ERBB-3 receptor, thereby blocking its activation and downstream signaling pathways.

This product has been extensively studied in preclinical and clinical trials, and has demonstrated remarkable efficacy in inhibiting tumor growth and metastasis. It has also been shown to enhance the effectiveness of other cancer therapies, such as chemotherapy and radiation therapy.

The ERBB-3 Monoclonal Antibody is available in various formulations and dosages to meet the specific needs of different patients and treatment regimens. It is administered intravenously and is generally well-tolerated, with minimal side effects.

In summary, the ERBB-3 Monoclonal Antibody is a cutting-edge therapeutic option for cancer patients, offering targeted and effective treatment with minimal adverse effects. Its proven efficacy and safety make it a valuable addition to any cancer treatment regimen.